Citigroup’s Acurx Pharmaceuticals ACXP Stock Holding History

Citigroup’s Portfolio ACXP Stock Details ACXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$4	–	5684
2026 Q1	$4	Hold	1	–	–	﹤0.01%	5784
2025 Q4	$2	Sell	1 -452	-100%	-$2.17K	﹤0.01%	5917
2025 Q3	$1.94K	Buy	+453	New	+$2.73K	﹤0.01%	5494

Other funds holding ACXP

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

PFS

Prospect Financial Services Melville, New York $197M AUM 24.49% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

WIM

Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return

NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Citigroup's ACXP Position: Q2 2026 in Review

Citigroup sold out of Acurx Pharmaceuticals (ACXP) in Q2 2026, closing a stake of 1 share — an estimated $4 sold.

Citigroup first reported a position in ACXP in Q3 2025 and held it in 3 quarters. The position peaked at $1.94K in Q3 2025. 18 funds tracked by Wall St. Rank hold ACXP as of Q2 2026.

Citigroup reported no remaining Acurx Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Citigroup sold 1 Acurx Pharmaceuticals share in Q2 2026, an estimated $4.
Citigroup first reported a position in Acurx Pharmaceuticals in Q3 2025 and held it in 3 quarters.
Citigroup's Acurx Pharmaceuticals position peaked at $1.94K in Q3 2025.
18 funds tracked by Wall St. Rank held Acurx Pharmaceuticals as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.